Table 2.
Characteristics of heart disease, pharmacological treatment at three months of follow-up, pre- and post-initial follow-up admissions and exitus.
| Heart Failure Characteristics | N (%) | |
|---|---|---|
| LVEF * (N = 407) | Preserved (≥50%) | 308 (74.6) |
| Slightly reduced (41–49%) | 36 (8.7) | |
| Reduced (<40%) | 62 (15.0) | |
| NYHA* ≥ 3 (N = 398) | 147 (36.9) | |
| Debut heart failure (N = 413) | 107 (25.9) | |
| Echocardiography (N = 413) | 401 (97.1) | |
| Heart disease aetiology (N = 405) | N (%) | |
| Ischaemic | 116 (28.6) | |
| Hypertensive | 312 (77.0) | |
| Valvular | 181 (44.7) | |
| Infiltrative | 24 (5.9) | |
| Valvulopathy (N = 377) | N (%) | |
| Aortic stenosis | 81 (21.5) | |
| Aortic insufficiency | 100 (26.5) | |
| Mitral stenosis | 16 (4.2) | |
| Mitral insufficiency | 215 (57.0) | |
| Tricuspid insufficiency | 153 (40.6) | |
| Pharmacological treatment | N (%) | |
| Beta-blockers | 258 (63.5) | |
| Angiotensin-converting enzyme inhibitors (ACE inhibitors) | 40 (9.9) | |
| Angiotensin 2 receptor antagonists (ARA2) | 98 (24.1) | |
| Angiotensin–Neprilysin Receptor Inhibitor (ARNI) | 47 (11.6) | |
| Antialdosteronics | 178 (43.8) | |
| Sodium-glucose co-transporter type 2 inhibitors (iSGLT2) | 107 (26.4) | |
| Loop diuretics | 362 (89.2) | |
| Thiazides | 35 (8.6) | |
| Anticoagulants | 261 (64.3) | |
| Anti-aggregants | 109 (26.8) | |
| Statins | 220 (54.2) | |
| Admissions and deaths | n (%) | |
| Admission prior to follow-up for heart failure (N = 411) | 258 (62.5) | |
| Admission in year prior to start of follow-up for heart failure (N = 409) | 219 (53.0) | |
| Admission for heart failure in the first year thereafter (N = 304) | 31 (7.5) | |
| Deaths (N = 413) | 256 (62.0) | |
* LVEF: left ventricular ejection fraction; NYHA: New York Heart Association.